{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T07:20:47Z","timestamp":1770794447898,"version":"3.50.0"},"reference-count":25,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T00:00:00Z","timestamp":1746489600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Am J Nephrol"],"abstract":"<jats:p>Introduction: Erythropoietin and roxadustat are commonly used to manage anemia in hemodialysis-dependent chronic kidney disease (CKD) patients, but the comparative safety and effectiveness are unknown. Methods: This is a retrospective cohort study. Data were extracted from Tianjin Healthcare and Medical Big Data Platform. We screened all patients with CKD stage G5 and anemia (hemoglobin &lt;100 g\/L) who were treated with either erythropoietin or roxadustat between January 1, 2015, and December 31, 2021. The primary endpoints included expanded composite of major adverse cardiovascular events (MACE+), cardio-cerebrovascular events, and thromboembolic events in the peridialytic period, defined as the duration from the time of estimated glomerular filtration rate decrease to &lt;15 mL\/min \u00d7 1.73 m2 to 3 months after dialysis initiation. A propensity score-matched analysis (1:1 ratio; caliper width: 0.02) was conducted to minimize the impact of confounding factors. Results: The initial screen identified a total of 40,324 patients; 1,092 were included in the propensity score-matched analysis (546 in each group). In comparison to the roxadustat group, the erythropoietin group had a lower rate of MACE+ events within 6 months (13.4% vs. 21.2%, p &lt; 0.001) and 12 months of treatment initiation (17.0% vs. 24.0%, p = 0.004), as well as within 3 months of hemodialysis initiation (12.9% vs. 28.7%, p &lt; 0.001). The rate of cardio-cerebrovascular events was also lower in the erythropoietin group within 6 months (38.5% vs. 50.7%, p &lt; 0.001) and 12 months of treatment initiation (49.1% vs. 56.2%, p &lt; 0.001). The rate of thromboembolic events did not differ between the two groups. Conclusion: Peridialytic erythropoietin was associated with a more favorable cardiovascular safety profile versus roxadustat in hemodialysis-dependent CKD patients.<\/jats:p>","DOI":"10.1159\/000546158","type":"journal-article","created":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T12:01:43Z","timestamp":1746619303000},"page":"81-95","source":"Crossref","is-referenced-by-count":0,"title":["Peridialytic Erythropoietin versus Roxadustat in Hemodialysis-Dependent Chronic Kidney Disease Patients"],"prefix":"10.1159","volume":"57","author":[{"given":"Lihua","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yueqi","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weijie","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4307-0987","authenticated-orcid":false,"given":"Chuanming","family":"Hao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4132-9406","authenticated-orcid":false,"given":"Cheng","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changlin","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2025,5,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/kisup.2015.2"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/sdi.12719"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000095676.90936.80"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvad083"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2011111078"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1186\/s12882-015-0138-x"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2016.05.031"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1159\/000380972"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907845"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065485"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/s41581-019-0182-z"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1901713"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.12888"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/1744-9987.13468"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2020111638"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01904-6"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.08280621"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.1037564"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2006.12.005"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/00273171.2011.568786"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-018-1632-9"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1007\/s10157-018-1649-0"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ekir.2020.01.007"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/961978"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01903-7"}],"container-title":["American Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000546158","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000546158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:01:34Z","timestamp":1770742894000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000546158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,6]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2,10]]},"published-print":{"date-parts":[[2026,2,4]]}},"URL":"https:\/\/doi.org\/10.1159\/000546158","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.28943003","asserted-by":"subject"}]},"ISSN":["0250-8095","1421-9670"],"issn-type":[{"value":"0250-8095","type":"print"},{"value":"1421-9670","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,6]]}}}